Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.57 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in cytotrophoblasts | 0.75 |
| chemistry Open Targets | compounds already reach it: droxidopa, propafenone, carvedilol +62 | 1.00 |
| trials ClinicalTrials.gov | 19 Parkinson's trials, 5 stopped | 0.79 |
| literature PubMed | 3 Parkinson's papers of 503 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11457
Earlier readings: 2026-10-26 0.51; 2026-10-25 0.51; 2026-10-24 0.51; 2026-10-23 0.52.
Sealed predictions
- ADRB1 in astrocytes, braak+0.01 (p 0.982) → -0.50 (p 0.172)receipt 0575
- ADRB1 in dopamine neurons, braak+0.08 (p 0.838) → -0.12 (p 0.761)receipt 0576
- ADRB1 in astrocytes, braak-0.06 (p 0.726) → -0.22 (p 0.168)receipt 0110
- ADRB1 in astrocytes, resilience-0.19 (p 0.468) → +0.19 (p 0.542)receipt 0111
Swarm cases
receipt 0576: ADRB1 in dopamine neurons, braak
- power
- full sample +0.07 (p 0.787, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.09 (p 0.715, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.00 (p 0.990, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.16, sign flips 3; without severely affected donors +0.07 (p 0.787, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADRB1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0575: ADRB1 in astrocytes, braak
- power
- full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.20 (p 0.434, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.24 (p 0.341, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.08, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADRB1 in astrocytes.
case closed: nothing better to follow up.
receipt 0111: ADRB1 in astrocytes, resilience
- power
- full sample -0.02 (p 0.916, n 55), 95% CI -0.28 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.05 (p 0.817, n 55). does not hold up.
- composition
- astrocytes share of nuclei vs axis +0.34 (p 0.084); controlling for it: +0.07 (p 0.705, n 55). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.07, sign flips 8; without severely affected donors -0.02 (p 0.928, n 46). fragile.
- cell type
- strongest in dopamine neurons: +0.54 (p 0.0062, n 55) vs -0.02 in astrocytes. proposing dopamine neurons.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for ADRB1 in astrocytes.
follow-up registered; not confirmed in ventral tegmental area.
follow-up ADRB1 · dopamine neurons · resilience: ventral tegmental area +0.17 p 0.345 (needs p < 0.0029)
receipt 0110: ADRB1 in astrocytes, braak
- power
- full sample -0.12 (p 0.290, n 84), 95% CI -0.32 to +0.10. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.12 (p 0.269, n 84). does not hold up.
- composition
- astrocytes share of nuclei vs axis +0.26 (p 0.016); controlling for it: -0.09 (p 0.435, n 84). could be the mix.
- skeptic
- leave-one-out range -0.15 to -0.09, sign flips 0; without severely affected donors -0.13 (p 0.274, n 75). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADRB1 in astrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts